5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      GPCR activation mechanisms across classes and macro/microscales

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Two-thirds of human hormones and one-third of clinical drugs activate ~350 G-protein-coupled receptors (GPCR) belonging to four classes: A, B1, C and F. Whereas a model of activation has been described for class A, very little is known about the activation of the other classes, which differ by being activated by endogenous ligands bound mainly or entirely extracellularly. Here we show that, although they use the same structural scaffold and share several ‘helix macroswitches’, the GPCR classes differ in their ‘residue microswitch’ positions and contacts. We present molecular mechanistic maps of activation for each GPCR class and methods for contact analysis applicable for any functional determinants. This provides a superfamily residue-level rationale for conformational selection and allosteric communication by ligands and G proteins, laying the foundation for receptor-function studies and drugs with the desired modality.

          Abstract

          Comparative analysis of inactive/active-state structures reveals molecular mechanistic maps of activation of the major GPCR classes. The findings and new approaches lay the foundation for targeted receptor-function studies and drugs with desired modalities.

          Related collections

          Most cited references57

          • Record: found
          • Abstract: found
          • Article: not found

          High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor.

          Heterotrimeric guanine nucleotide-binding protein (G protein)-coupled receptors constitute the largest family of eukaryotic signal transduction proteins that communicate across the membrane. We report the crystal structure of a human beta2-adrenergic receptor-T4 lysozyme fusion protein bound to the partial inverse agonist carazolol at 2.4 angstrom resolution. The structure provides a high-resolution view of a human G protein-coupled receptor bound to a diffusible ligand. Ligand-binding site accessibility is enabled by the second extracellular loop, which is held out of the binding cavity by a pair of closely spaced disulfide bridges and a short helical segment within the loop. Cholesterol, a necessary component for crystallization, mediates an intriguing parallel association of receptor molecules in the crystal lattice. Although the location of carazolol in the beta2-adrenergic receptor is very similar to that of retinal in rhodopsin, structural differences in the ligand-binding site and other regions highlight the challenges in using rhodopsin as a template model for this large receptor family.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Trends in GPCR drug discovery: new agents, targets and indications

            G protein-coupled receptors (GPCRs) are the most intensively studied drug targets, largely due to their substantial involvement in human pathophysiology and their pharmacological tractability. Here, we report the first analysis of all GPCR drugs and agents in clinical trials. This reveals the current trends across molecule types, drug targets and therapeutic indications, including showing that 481 drugs (~34% of all drugs approved by the FDA) act at 107 unique GPCR targets. Approximately 320 agents are currently in clinical trials, of which ~36% target 64 potentially novel GPCR targets without an approved drug, and the number of biological drugs, allosteric modulators and biased agonists has grown. The major disease indications for GPCR modulators show a shift towards diabetes, obesity, and Alzheimer’s disease, while other central nervous system disorders remain highly represented. The 227 (57%) non-olfactory GPCRs that are yet to be explored in clinical trials have broad untapped therapeutic potential, particularly in genetic and immune system disorders. Finally, we provide an interactive online resource to analyse and infer trends in GPCR drug discovery.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Crystal structure of rhodopsin: A G protein-coupled receptor.

              Heterotrimeric guanine nucleotide-binding protein (G protein)-coupled receptors (GPCRs) respond to a variety of different external stimuli and activate G proteins. GPCRs share many structural features, including a bundle of seven transmembrane alpha helices connected by six loops of varying lengths. We determined the structure of rhodopsin from diffraction data extending to 2.8 angstroms resolution. The highly organized structure in the extracellular region, including a conserved disulfide bridge, forms a basis for the arrangement of the seven-helix transmembrane motif. The ground-state chromophore, 11-cis-retinal, holds the transmembrane region of the protein in the inactive conformation. Interactions of the chromophore with a cluster of key residues determine the wavelength of the maximum absorption. Changes in these interactions among rhodopsins facilitate color discrimination. Identification of a set of residues that mediate interactions between the transmembrane helices and the cytoplasmic surface, where G-protein activation occurs, also suggests a possible structural change upon photoactivation.
                Bookmark

                Author and article information

                Contributors
                david.gloriam@sund.ku.dk
                Journal
                Nat Struct Mol Biol
                Nat Struct Mol Biol
                Nature Structural & Molecular Biology
                Nature Publishing Group US (New York )
                1545-9993
                1545-9985
                10 November 2021
                10 November 2021
                2021
                : 28
                : 11
                : 879-888
                Affiliations
                [1 ]GRID grid.5254.6, ISNI 0000 0001 0674 042X, Department of Drug Design and Pharmacology, , University of Copenhagen, ; Copenhagen, Denmark
                [2 ]GRID grid.168010.e, ISNI 0000000419368956, Department of Molecular and Cellular Physiology, , Stanford University School of Medicine, ; Stanford, CA USA
                [3 ]GRID grid.14848.31, ISNI 0000 0001 2292 3357, Department of Biochemistry and Molecular Medicine, Institute for Research in Immunology and Cancer, , Université de Montréal, ; Montreal, Quebec Canada
                [4 ]GRID grid.42475.30, ISNI 0000 0004 0605 769X, Laboratory of Molecular Biology, Cambridge Biomedical Campus, ; Cambridge, UK
                [5 ]GRID grid.4563.4, ISNI 0000 0004 1936 8868, Centre of Membrane Proteins and Receptors (COMPARE), , University of Nottingham, ; Nottingham, UK
                [6 ]GRID grid.4563.4, ISNI 0000 0004 1936 8868, Division of Physiology, Pharmacology & Neuroscience, School of Life Sciences, , University of Nottingham, ; Nottingham, UK
                [7 ]GRID grid.240871.8, ISNI 0000 0001 0224 711X, Department of Structural Biology and Center for Data Driven Discovery, , St. Jude Children’s Research Hospital, ; Memphis, TN USA
                [8 ]GRID grid.10582.3e, ISNI 0000 0004 0373 0797, Present Address: Data Tools Department, Novozymes A/S, ; Copenhagen, Denmark
                Author information
                http://orcid.org/0000-0003-1098-6419
                http://orcid.org/0000-0001-5514-6021
                http://orcid.org/0000-0002-8049-4383
                http://orcid.org/0000-0003-1128-0100
                http://orcid.org/0000-0003-0556-6196
                http://orcid.org/0000-0002-4299-7561
                Article
                674
                10.1038/s41594-021-00674-7
                8580822
                34759375
                c3edd8da-5e0e-4ff0-8ccd-af192c3be7bc
                © The Author(s) 2021

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 23 March 2021
                : 22 September 2021
                Categories
                Article
                Custom metadata
                © The Author(s), under exclusive licence to Springer Nature America, Inc. 2021

                Molecular biology
                structural biology,computational biology and bioinformatics,molecular biology,drug discovery

                Comments

                Comment on this article